skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 3,447  for All Library Resources

Results 1 2 3 4 5 next page
Show only
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
Material Type:
Article
Add to My Research

Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

The New England journal of medicine, 2017-05, Vol.376 (18), p.1723-1736 [Peer Reviewed Journal]

Copyright © 2017 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1606910 ;PMID: 28467869

Full text available

2
Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial
Material Type:
Article
Add to My Research

Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial

The lancet oncology, 2020-07, Vol.21 (7), p.935-946 [Peer Reviewed Journal]

2020 Elsevier Ltd ;Copyright © 2020 Elsevier Ltd. All rights reserved. ;2020. Elsevier Ltd ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(20)30269-2 ;PMID: 32615108

Full text available

3
Clinical significance of Janus Kinase inhibitor selectivity
Material Type:
Article
Add to My Research

Clinical significance of Janus Kinase inhibitor selectivity

Rheumatology (Oxford, England), 2019-06, Vol.58 (6), p.953-962 [Peer Reviewed Journal]

The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Rheumatology. ;The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Rheumatology. 2018 ;ISSN: 1462-0324 ;EISSN: 1462-0332 ;DOI: 10.1093/rheumatology/key339 ;PMID: 30508136

Full text available

4
Clinicogenomic Analysis of FGFR2 -Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib
Material Type:
Article
Add to My Research

Clinicogenomic Analysis of FGFR2 -Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib

Cancer discovery, 2021-02, Vol.11 (2), p.326-339

2020 American Association for Cancer Research. ;ISSN: 2159-8274 ;EISSN: 2159-8290 ;DOI: 10.1158/2159-8290.cd-20-0766 ;PMID: 33218975

Full text available

5
Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma
Material Type:
Article
Add to My Research

Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma

The New England journal of medicine, 2018-08, Vol.379 (5), p.417-427 [Peer Reviewed Journal]

Copyright © 2018 Massachusetts Medical Society. All rights reserved. ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1803675 ;PMID: 29860937

Full text available

6
Ubrogepant for the Treatment of Migraine
Material Type:
Article
Add to My Research

Ubrogepant for the Treatment of Migraine

The New England journal of medicine, 2019-12, Vol.381 (23), p.2230-2241 [Peer Reviewed Journal]

Copyright © 2019 Massachusetts Medical Society. All rights reserved. ;Copyright © 2019 Massachusetts Medical Society. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1813049 ;PMID: 31800988

Full text available

7
Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis
Material Type:
Article
Add to My Research

Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis

Rheumatology (Oxford, England), 2018-12, Vol.57 (12), p.2114-2119 [Peer Reviewed Journal]

The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com 2018 ;ISSN: 1462-0324 ;EISSN: 1462-0332 ;DOI: 10.1093/rheumatology/key188 ;PMID: 30060040

Full text available

8
Acid‐inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects ‐ a randomised open‐label cross‐over study
Material Type:
Article
Add to My Research

Acid‐inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects ‐ a randomised open‐label cross‐over study

Alimentary pharmacology & therapeutics, 2015-09, Vol.42 (6), p.719-730 [Peer Reviewed Journal]

2015 The Authors. published by John Wiley & Sons Ltd. ;2015 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd. ;ISSN: 0269-2813 ;EISSN: 1365-2036 ;DOI: 10.1111/apt.13325 ;PMID: 26193978

Full text available

9
Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis
Material Type:
Article
Add to My Research

Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis

Journal of investigative dermatology, 2014-12, Vol.134 (12), p.2988-2990 [Peer Reviewed Journal]

2014 The Society for Investigative Dermatology, Inc ;Copyright Nature Publishing Group Dec 2014 ;ISSN: 0022-202X ;EISSN: 1523-1747 ;DOI: 10.1038/jid.2014.260 ;PMID: 24940651

Full text available

10
Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN): Phase 3 Randomized Controlled Clinical Trial
Material Type:
Article
Add to My Research

Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN): Phase 3 Randomized Controlled Clinical Trial

Clinical journal of the American Society of Nephrology, 2020-12, Vol.15 (12), p.1715-1727 [Peer Reviewed Journal]

Copyright © 2020 by the American Society of Nephrology. ;Copyright © 2020 by the American Society of Nephrology 2020 ;ISSN: 1555-9041 ;EISSN: 1555-905X ;DOI: 10.2215/CJN.06870520 ;PMID: 33239409

Full text available

11
Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan
Material Type:
Article
Add to My Research

Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan

Gut, 2020-06, Vol.69 (6), p.1019-1026 [Peer Reviewed Journal]

Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. ;2020 Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2020 ;ISSN: 0017-5749 ;EISSN: 1468-3288 ;DOI: 10.1136/gutjnl-2019-319954 ;PMID: 31915235

Full text available

12
Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial
Material Type:
Article
Add to My Research

Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial

The lancet oncology, 2020-10, Vol.21 (10), p.1296-1308 [Peer Reviewed Journal]

2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license ;Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. ;2020. The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. This work is published under https://creativecommons.org/licenses/by/3.0/ (theLicense”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license 2020 ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(20)30444-7 ;PMID: 32919527

Full text available

13
Targeting renal cell carcinoma with a HIF-2 antagonist
Material Type:
Article
Add to My Research

Targeting renal cell carcinoma with a HIF-2 antagonist

Nature (London), 2016-11, Vol.539 (7627), p.112-117 [Peer Reviewed Journal]

COPYRIGHT 2016 Nature Publishing Group ;COPYRIGHT 2016 Nature Publishing Group ;ISSN: 0028-0836 ;EISSN: 1476-4687 ;DOI: 10.1038/nature19796 ;PMID: 27595394

Full text available

14
The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis
Material Type:
Article
Add to My Research

The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis

Clinical and experimental rheumatology, 2016-03, Vol.34 (2), p.318-328 [Peer Reviewed Journal]

ISSN: 0392-856X ;EISSN: 1593-098X ;PMID: 26966791

Full text available

15
Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors
Material Type:
Article
Add to My Research

Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors

The New England journal of medicine, 2017-10, Vol.377 (16), p.1525-1536 [Peer Reviewed Journal]

Copyright © 2017 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1615977 ;PMID: 29045207

Full text available

16
Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid Arthritis
Material Type:
Article
Add to My Research

Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid Arthritis

Arthritis & rheumatology (Hoboken, N.J.), 2014-10, Vol.66 (10), p.2675-2684 [Peer Reviewed Journal]

2014 The Authors. Arthritis & Rheumatology is published by Wiley Periodicals, Inc. on behalf of the American College of Rheumatology. ;Copyright © 2014 by the American College of Rheumatology ;2014 The Authors. Arthritis & Rheumatology is published by Wiley Periodicals, Inc. on behalf of the American College of Rheumatology. 2014 ;ISSN: 2326-5191 ;EISSN: 2326-5205 ;DOI: 10.1002/art.38745 ;PMID: 24943354

Full text available

17
Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial
Material Type:
Article
Add to My Research

Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial

The Lancet (British edition), 2017-07, Vol.390 (10093), p.457-468 [Peer Reviewed Journal]

Elsevier Ltd ;2017 Elsevier Ltd ;Copyright © 2017 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Jul 29, 2017 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(17)31618-5 ;PMID: 28629665

Full text available

18
The emerging safety profile of JAK inhibitors in rheumatic disease
Material Type:
Article
Add to My Research

The emerging safety profile of JAK inhibitors in rheumatic disease

Nature reviews. Rheumatology, 2017-04, Vol.13 (4), p.234-243 [Peer Reviewed Journal]

COPYRIGHT 2017 Nature Publishing Group ;COPYRIGHT 2017 Nature Publishing Group ;Copyright Nature Publishing Group Apr 2017 ;ISSN: 1759-4790 ;EISSN: 1759-4804 ;DOI: 10.1038/nrrheum.2017.23 ;PMID: 28250461

Full text available

19
AKT Inhibition in Solid Tumors With AKT1 Mutations
Material Type:
Article
Add to My Research

AKT Inhibition in Solid Tumors With AKT1 Mutations

Journal of clinical oncology, 2017-07, Vol.35 (20), p.2251-2259 [Peer Reviewed Journal]

2017 by American Society of Clinical Oncology 2017 American Society of Clinical Oncology ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2017.73.0143 ;PMID: 28489509

Full text available

20
Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF / FGFR Aberrations: A Phase I Dose-Expansion Study
Material Type:
Article
Add to My Research

Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF / FGFR Aberrations: A Phase I Dose-Expansion Study

Cancer discovery, 2022-02, Vol.12 (2), p.402-415

2021 The Authors; Published by the American Association for Cancer Research. ;Attribution - NonCommercial - NoDerivatives ;2021 The Authors; Published by the American Association for Cancer Research 2021 American Association for Cancer Research ;ISSN: 2159-8274 ;EISSN: 2159-8290 ;DOI: 10.1158/2159-8290.CD-21-0697 ;PMID: 34551969

Full text available

Results 1 - 20 of 3,447  for All Library Resources

Results 1 2 3 4 5 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Show only

  1. Peer-reviewed Journals (3,220)

Refine My Results

Creation Date 

From To
  1. Before 1977  (24)
  2. 1977 To 1988  (72)
  3. 1989 To 2000  (185)
  4. 2001 To 2013  (2,206)
  5. After 2013  (962)
  6. More options open sub menu

Language 

  1. English  (3,352)
  2. Japanese  (588)
  3. French  (28)
  4. German  (24)
  5. Spanish  (22)
  6. Portuguese  (12)
  7. Russian  (10)
  8. Italian  (7)
  9. Polish  (5)
  10. Turkish  (4)
  11. Hungarian  (1)
  12. Swedish  (1)
  13. Ukrainian  (1)
  14. Slovak  (1)
  15. Czech  (1)
  16. More options open sub menu

Searching Remote Databases, Please Wait